Skip to main content
. 2019 Jul 12;317(3):H617–H626. doi: 10.1152/ajpheart.00177.2019

Fig. 6.

Fig. 6.

Changes in apoptotic and mitochondrial markers after drug treatments in chemogenetic heart failure. A: representative immunoblots of caspase-3 in control or d-amino acid oxidase (DAAO)-expressing rats or in DAAO-expressing rats treated with sacubitril/valsartan (Sac/val) or valsartan (Val). B: quantitative data of caspase-3 protein levels in control (n = 3) or DAAO-expressing rats (n = 6) or in DAAO-expressing rats treated with sacubitril/valsartan (n = 6) or valsartan (n = 5). *P < 0.05, ***P < 0.001 obtained by one-way ANOVA with Šídák’s multiple-comparison test. C: representative immunoblots of isocitrate dehydrogenase 2 (Idh2) in control or DAAO-expressing rats or in DAAO-expressing rats treated with sacubitril/valsartan or valsartan. D: quantitative data of Idh2 protein levels in control (n = 3) or DAAO-expressing rats (n = 6) or in DAAO-expressing rats treated with sacubitril/valsartan (n = 6) or valsartan (n = 5). **P < 0.01 obtained by one-way ANOVA with Šídák’s multiple-comparison test. E: quantitative data of Idh2 transcript levels in control (n = 3) or DAAO-expressing rats (n = 6) or in DAAO-expressing rats treated with sacubitril/valsartan (n = 6) or valsartan (n = 5). ***P < 0.001 obtained by one-way ANOVA with Šídák’s multiple-comparison test. Data are represented as means ± SE.